Recent Lung Cancer - Non-Small Cell News

First Line Combination Therapy Improves Progression-Free Survival In Advanced Lung Cancer (January 8, 2018)

A recently reported study confirms that combination therapy using the “checkpoint inhibitor” Tecentriq® (atezolizumab) and chemotherapy as first line treatment for advanced non-squamous non-small-cell... Continue Reading

The Role of Immunotherapy in the Treatment of Advanced Non Small Cell Lung Cancer (December 6, 2017)

Treatment options for advanced NSCLC fit into 3 main categories… Targeted Therapy – we test lung cancer for specific mutations to see if we have an appropriate targeted medication. Immunotherapy –... Continue Reading

Alcensa Precision Medicine Approved for (ALK) Positive Non-Small Cell Lung Cancer (November 13, 2017)

The Food and Drug Administration granted regular approval to Alcensa (alectinib), for treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC),... Continue Reading

Alecensa Appears Superior to Xalkori in ALK positive NSCLC Involving the Brain (September 21, 2017)

The results from two separate clinical studies comparing Alecensa® (alectinib) to Xalkori (crizotinib) presented at the European Society for Medical Oncology in Madrid demonstrate that Alecensa®  s... Continue Reading

FDA grants regular approval to dabrafenib and trametinib combination for metastatic NSCLC with BRAF V600E mutation (June 26, 2017)

The U.S. Food and Drug Administration granted regular approvals to Tafinlar® (dabrafenib) and Mekinist® (trametinib) administered in combination for patients with metastatic non-small cell lung cancer... Continue Reading

Alecensa Superior to Xalkori in Treatment of Lung Cancer (June 12, 2017)

Alecensa (alectinib) halted the spread of lung cancer for a median of 15 months longer than treatment with rival Xalkori (crizotinib) with fewer side effects, according to trial results presented at the... Continue Reading

Radiation Therapy can Enhance Effectiveness of Immunotherapy in People With Advanced Lung Cancer (June 2, 2017)

UCLA RESEARCH ALERT FINDINGS A new study by UCLA scientists has found that the breakthrough immunotherapy drug Keytruda (pembrolizumb)  can be more effective in improving survival in people with non-small... Continue Reading

Imfinzi Improves Outcomes for Patients With Stage III Non Small Cell Lung Cancer (May 30, 2017)

Positive results for the PACIFIC clinical trial evaluating the novel precision medicine, Imfinzi (durvalumab) as sequential treatment in patients with Stage III non-small cell lung cancer (NSCLC) who... Continue Reading

Tagrisso Approved for Treatment of Certain Lung Cancers (April 18, 2017)

The U.S. Food and Drug Administration granted regular approval to Tagrisso (osimertinib) for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small... Continue Reading

Opdivo Appears to Significantly Improve Five-Year Survival Rates in Advanced Lung Cancer (April 13, 2017)

Treatment with the immune checkpoint inhibitor Opdivo (nivolumab) yielded durable responses in some patients with advanced non-small cell lung cancer (NSCLC), with a five-year survival rate of 16 percent,... Continue Reading

Next Page »